Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells

ABCB1 overexpression is known to contribute to multidrug resistance (MDR) in cancers. Therefore, it is critical to find effective drugs to target ABCB1 and overcome MDR. Erdafitinib is a tyrosine kinase inhibitor (TKI) of fibroblast growth factor receptor (FGFR) that is approved by the FDA to treat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Feng, Weiguo, Zhang, Meng, Wu, Zhuo-Xun, Wang, Jing-Quan, Dong, Xing-Duo, Yang, Yuqi, Teng, Qiu-Xu, Chen, Xuan-Yu, Cui, Qingbin, Yang, Dong-Hua
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7330633/
https://ncbi.nlm.nih.gov/pubmed/32670878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00955
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados